FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, | D.C. 20549 |
|-------------|------------|
|-------------|------------|

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

# **OMB APPROVAL** STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

3235-0287 Estimated average burden hours per response: 0.5

| Instruction 1  | (b).                  |                       | Filed pursuant to Section 16(a) of the Securities Exchange Act of 19 or Section 30(h) of the Investment Company Act of 1940 | 934  | nours per   | тезропас. 0.5                              |
|--|-----------------------|-----------------------|---|--|---|--|
| Name and Address of Reporting Person*     Sachdev Amit |                       | g Person <sup>*</sup> | 2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [ VRTX ]  |  | onship of Reporting Pers<br>all applicable)<br>Director<br>Officer (give title  | son(s) to Issuer  10% Owner Other (specify |
| (Last) C/O VERTE                                       | (First)<br>X PHARMACE | (Middle)              | 3. Date of Earliest Transaction (Month/Day/Year) 11/15/2023   | "  | below) below) EVP Chief Patient & Ext Af Off                                    |  |
| INCORPORATED<br>50 NORTHERN AVENUE                     |                       |                       | 4. If Amendment, Date of Original Filed (Month/Day/Year)  | 6. Indiv<br>Line)  | dual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person |  |
| (Street)   | MA                    | 02210                 |   |  | Form filed by More the Person   | nan One Reporting                          |
| BOSTON   | MA                    | 02210                 | Rule 10b5-1(c) Transaction Indication   |  |   |  |
| (City)   | (State)               | (Zip)                 |   | to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to mative defense conditions of Rule 10b5-1(c). See Instruction 10. |   |  |

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction 2A. Deemed 4. Securities Acquired (A) or 5. Amount of 6. Ownership 7. Nature Form: Direct (D) or Indirect of Indirect Beneficial Execution Date, Transaction Disposed Of (D) (Instr. 3, 4 and Securities Beneficially (Month/Day/Year) Code (Instr. if any 5) Owned Following (Month/Dav/Year) 8) (I) (Instr. 4) Ownership (Instr. 4) (A) or (D) Transaction(s) Price Code Amount (Instr. 3 and 4) $S^{(1)}$ Common Stock 11/15/2023 35 D \$369.92 58,814 D Common Stock 882 Ι 401(k) Held in 6,565 Common Stock Trust

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 7. Title and 1. Title of 3. Transaction 3A. Deemed 5. Number 6. Date Exercisable and 8. Price of 9. Number of 10. 11. Nature Conversion Execution Date, Transaction **Expiration Date** Amount of Derivative Ownership derivative of Indirect Derivative (Month/Day/Year) Security or Exercise if any (Month/Day/Year) Code (Instr. Derivative (Month/Day/Year) Securities Security Securities Form: Beneficial Price of Derivative Securities Acquired Direct (D) or Indirect Ownership (Instr. 4) 8) Underlying (Instr. 5) Beneficially Derivative Owned (A) or Disposed Security (Instr. 3 and 4) (I) (Instr. 4) Security Following Reported of (D) (Instr. 3, 4 and 5) Transaction(s) (Instr. 4) Amount Number Expiration Code (A) (D) Exercisable Title **Shares** Date

### **Explanation of Responses:**

### Remarks:

/s/ Christiana Stevenson, 11/17/2023 Attorney-in-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>1.</sup> Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023.